Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04914676 · ClinicalTrials.gov registry record · Phase 2
Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission
A Phase 2 study, sponsored by University of Florida.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT04914676 is a Phase 2 study that was terminated before completion, run by University of Florida. The registered enrollment target is 5 participants.
The verdict
NCT04914676, a Phase 2 study, was terminated before completion, sponsored by University of Florida.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This phase 2, open label, non-randomized study will evaluate the safety of administering high dose cytarabine (HiDAC) consolidation therapy on days 1-3 of each cycle, as compared to standard administration on days 1, 3, and 5 of each cycle, in patients 61 years and older with de novo acute myeloid leukemia (AML).
Interventions
- DRUG Cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2022-03-08 |
| Est. Completion | 2024-08-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04914676
The ClinicalTrials.gov registry entry for NCT04914676 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cytarabine is the first listed.
NCT04914676 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04914676 about?
NCT04914676 is a clinical study titled "Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission". This phase 2, open label, non-randomized study will evaluate the safety of administering high dose cytarabine (HiDAC) consolidation therapy on days 1-3 of each cycle, as compared to standard administration on days 1, 3, and 5 of each cycle, in patients 61 years and older with de novo acute myeloid l...
What is the current status of trial NCT04914676?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2022-03-08. Estimated completion is 2024-08-26.
What interventions are being tested in trial NCT04914676?
The interventions under investigation include: Cytarabine (DRUG).
Who is sponsoring clinical trial NCT04914676?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.